No Data
No Data
No Data
No Data
No Data
Schrodinger Gets Rights to Cancer Drug Candidate Back From Bristol
Seeking Alpha03:04
Schrodinger Price Target Cut to $30.00/Share From $35.00 by Craig-Hallum
Schrodinger Price Target Cut to $30.00/Share From $35.00 by Craig-Hallum
Dow Jones01:10
Schrodinger Is Maintained at Buy by Craig-Hallum
Schrodinger Is Maintained at Buy by Craig-Hallum
Dow Jones01:10
Craig-Hallum: Maintaining the Schrodinger (SDGR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $35.00 to $30.00.
Craig-Hallum: Maintaining the Schrodinger (SDGR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $35.00 to $30.00.
Zhitong Finance01:00
Craig-Hallum Maintains Buy on Schrodinger, Lowers Price Target to $30
Craig-Hallum analyst Matt Hewitt maintains Schrodinger (NASDAQ:SDGR) with a Buy and lowers the price target from $35 to $30.
Benzinga00:59
Schrodinger Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 30.66% Craig-Hallum $35 → $30 Maintains Buy 03/01/2024 69.86% Citigroup $47 → $39 Maintains Buy
Benzinga00:59
No Data
No Data